ProtoKinetix Receives Independent Confirmation of AAGP Anti-Inflammatory Action
VANCOUVER, British Columbia, Nov. 10 /CNW/ -- ProtoKinetix Inc. (OTC Bulletin Board: PKTX), a biotech company focused on the research, development and commercialization of patented anti-aging glycopeptides (AAGPs(TM)) announced today that its Director of Science Dr. Geraldine Deliencourt has received results of tests conducted by a major independent laboratory in France to determine the biological activity of AAGP(TM) on the selectin inflammation pathway.
The highly specific tests conducted on selectin showed 100% adhesion inhibition. Diseases such as Alzheimer's, Chron's, diabetes, arthritis, cancer and cardiovascular problems are among the many life-threatening conditions treated with anti-inflammation and selectin inhibition therapies. These results are consistent with previous tests conducted using extremely hostile stresses.
Repeatedly, the presence of AAGP(TM) has shown its ability to protect cells under the most adverse of conditions. Dr. Deliencourt said, "The results obtained broaden the impact and scope of the applications of AAGP(TM). They will also help us clarify the mechanism of action of AAGP(TM) and seem to be consistent with all of the previous results we have obtained." She further explains that these results indicate that AAGP(TM) could be both an adhesion inhibitor and an anti-oxidant. Ross Senior, President and CEO of ProtoKinetix, said, "The control of inflammation is of vital importance to the treatment of a number of immune complex mediated diseases.
AAGP(TM) continues to demonstrate its potential to become a major contributor in the successful treatment of a wide range of health problems." << About ProtoKinetix >> ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycoproteins (AAGP(TM)) for medicine and the biotechnology and cosmetic industries. PKTX is currently in dialogue with major corporations and institutions who have contacted the company about the broad range of applications for AAGP(TM) products.
For more detailed information, please visit our website at www.protokinetix.com. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.
<< Company contact: Investor Relations contact: Blair Henderson, ProtoKinetix, Inc. Rick McCaffrey, OTC Financial Network 604-687-9887 781-444-6100x625 firstname.lastname@example.org
/For further information: Blair Henderson, ProtoKinetix, Inc., +1-604-687-9887, email@example.com
Posted: November 2008